XPO1 and neurodegenerative disease: Among these XPO1 inhibitors, the compound KPT-330 (Selinexor, Karyopharm Therapeutics) can cross the blood-brain barrier, which highlights its potential against neurodegenerative diseases (Green et al., 2015).